Dr. Tepedino is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1400 E. Hartley St
High Point, NC 27262Phone+1 336-802-2020Fax+1 336-802-2021
Education & Training
New York Medical College at St Vincent's Hospital and Medical Center of New YorkResidency, Ophthalmology, 1990 - 1993
NYU Grossman Long Island School of MedicineInternship, Internal Medicine, 1989 - 1990- New York Medical CollegeClass of 1989
Certifications & Licensure
NC State Medical License 1993 - 2025
NY State Medical License 1991 - 1994- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension Start of enrollment: 2010 Nov 01
- Safety and Efficacy Study of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders Start of enrollment: 2014 Apr 08
- Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID) Start of enrollment: 2014 Aug 01
Publications & Presentations
PubMed
- 4 citationsOmidenepag Isopropyl in Latanoprost Low/Nonresponders With Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 3, Nonrandomized, Two-Phase, Open-Label Study.Joseph F Panarelli, Eileen C Bowden, Michael E Tepedino, Noriko Odani-Kawabata, Zifan Pei
Journal of Glaucoma. 2023-12-01 - 8 citationsOral administration of the 11β-hydroxysteroid-dehydrogenase type 1 inhibitor RO5093151 to patients with glaucoma: an adaptive, randomised, placebo-controlled clinical ...Dietmar Schwab, Carolina Sturm, Agnès Portron, Sabine Fuerst-Recktenwald, Dominik Hainzl
BMJ Open Ophthalmology. 2017-06-01 - 58 citationsPhase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis.Michael Tepedino, Warren H. Heller, Dale W. Usner, Lynne Brunner, Timothy W. Morris
Current Medical Research and Opinion. 2009-04-29
Press Mentions
Program Helps Aspiring Healthcare Worker, High School Student Reach Her GoalMarch 29th, 2017
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
